Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avacta doubles revenues but loss widens

This article was originally published in Clinica

Executive Summary

Developer of analysis and detection technologies Avacta has doubled its revenues in fiscal 2009 after it began selling its first range of products earlier in the year, according to preliminary results. The York, UK-based firm launched Optim in April, an analytical instrument designed to assist drug developers to measure and predict in advance the biophysical implications of new therapeutic candidates. In its preliminary results for the full year, the firm’s revenues climbed from £0.466m ($0.8m) in 2008 to £0.944m this year, a 103% increase. Operating costs also went up prompting the bottom line to widen from a loss of £1.5m in 2008 to a loss of £2.7m this year. The company is planning to the roll-out of further complementary instruments for Optim in 2010 and 2011. Avacta is also looking to break into the point-of-care diagnostics market with its Midas device, which can detect protein markers of disease in biological fluids. The product is expected to be launched initially in the veterinary market in early 2010.

You may also be interested in...

Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts